ORNL’s electromagnetic isotope separator, or EMIS, made history in 2018 when it produced 500 milligrams of the rare isotope ruthenium-96, unavailable anywhere else in the world.
Three scientists from the Department of Energy’s Oak Ridge National Laboratory have been elected fellows of the American Association for the Advancement of Science, or AAAS.
A partnership of ORNL, the Tennessee Department of Economic and Community Development, the Community Reuse Organization of East Tennessee and TVA that aims to attract nuclear energy-related firms to Oak Ridge has been recognized with a state and local economic development award from the Federal Laboratory Consortium.
Although blockchain is best known for securing digital currency payments, researchers at the Department of Energy’s Oak Ridge National Laboratory are using it to track a different kind of exchange: It’s the first time blockchain has ever been used to validate communication among devices on the electric grid.
Nine student physicists and engineers from the #1-ranked Nuclear Engineering and Radiological Sciences Program at the University of Michigan, or UM, attended a scintillation detector workshop at Oak Ridge National Laboratory Oct. 10-13.
Laboratory Director Thomas Zacharia presented five Director’s Awards during Saturday night's annual Awards Night event hosted by UT-Battelle, which manages ORNL for the Department of Energy.
Three ORNL scientists have been elected fellows of the American Association for the Advancement of Science, or AAAS, the world’s largest general scientific society and publisher of the Science family of journals.
In experiment after experiment, the synthetic radioisotope actinium-225 has shown promise for targeting and attacking certain types of cancer cells.
An analysis published in the Proceedings of the National Academy of Sciences and led by researchers from the U.S. Department of Energy’s Oak Ridge National Laboratory has received the 2021 Sustainability Science Award from the Ecological Society of America.
A rare isotope in high demand for treating cancer is now more available to pharmaceutical companies developing and testing new drugs.